Development, validation and clinical usefulness of a prognostic model for relapse in relapsing-remitting multiple sclerosis. by Chalkou, Konstantina et al.
RESEARCH Open Access
Development, validation and clinical
usefulness of a prognostic model for
relapse in relapsing-remitting multiple
sclerosis
Konstantina Chalkou1* , Ewout Steyerberg2, Patrick Bossuyt3, Suvitha Subramaniam4, Pascal Benkert4,
Jens Kuhle5,6, Giulio Disanto7, Ludwig Kappos5, Chiara Zecca8,9, Matthias Egger1 and Georgia Salanti1
Abstract
Background: Prognosis for the occurrence of relapses in individuals with relapsing-remitting multiple sclerosis
(RRMS), the most common subtype of multiple sclerosis (MS), could support individualized decisions and disease
management and could be helpful for efficiently selecting patients for future randomized clinical trials. There are
only three previously published prognostic models on this, all of them with important methodological
shortcomings.
Objectives: We aim to present the development, internal validation, and evaluation of the potential clinical benefit
of a prognostic model for relapses for individuals with RRMS using real-world data.
Methods: We followed seven steps to develop and validate the prognostic model: (1) selection of prognostic
factors via a review of the literature, (2) development of a generalized linear mixed-effects model in a Bayesian
framework, (3) examination of sample size efficiency, (4) shrinkage of the coefficients, (5) dealing with missing data
using multiple imputations, (6) internal validation of the model. Finally, we evaluated the potential clinical benefit of
the developed prognostic model using decision curve analysis. For the development and the validation of our
prognostic model, we followed the TRIPOD statement.
Results: We selected eight baseline prognostic factors: age, sex, prior MS treatment, months since last relapse,
disease duration, number of prior relapses, expanded disability status scale (EDSS) score, and number of
gadolinium-enhanced lesions. We also developed a web application that calculates an individual’s probability of
relapsing within the next 2 years. The optimism-corrected c-statistic is 0.65 and the optimism-corrected calibration
slope is 0.92. For threshold probabilities between 15 and 30%, the “treat based on the prognostic model” strategy
leads to the highest net benefit and hence is considered the most clinically useful strategy.
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Conclusions: The prognostic model we developed offers several advantages in comparison to previously published
prognostic models on RRMS. Importantly, we assessed the potential clinical benefit to better quantify the clinical
impact of the model. Our web application, once externally validated in the future, could be used by patients and
doctors to calculate the individualized probability of relapsing within 2 years and to inform the management of
their disease.
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Introduction
Multiple sclerosis (MS) is an immune-mediated disease
of the central nervous system with several subtypes. The
most common subtype is relapsing-remitting multiple
sclerosis (RRMS) [1]. Patients with RRMS present with
acute or subacute symptoms (relapses) followed by pe-
riods of complete or incomplete recovery (remissions)
[2]. Effective treatment of patients with RRMS can pre-
vent disease progression and associated severe conse-
quences, like spasticity, fatigue, cognitive dysfunction,
depression, bladder dysfunction, bowel dysfunction, sex-
ual dysfunction, pain, and death [3].
Relapses have been commonly used as a primary effi-
cacy endpoint in phase III randomized clinical trials
leading to market approval of RRMS therapies, although
the strength of the association between relapses and dis-
ease progression (an outcome of highest interest to pa-
tients) is still debated [4, 5, 6]. Prognosis for relapses in
individuals with RRMS could support individualized de-
cisions and disease management. A prognostic model for
relapses may also be helpful for the efficient selection of
patients in future randomized clinical trials and, there-
fore, for the reduction of type II errors in these trials [7].
In addition, such a model could support individualized
decisions on initiation or switch of disease-modifying
treatment (DMT). To our knowledge, no widely ac-
cepted prognostic model for MS has been used in clin-
ical practice yet.
A recent systematic review of prediction models in
RRMS [8] identified only three prognostic models (i.e.
models that focus on predicting the outcome instead of
predicting treatment response) with relapses as the out-
come of interest [7, 9, 10]. However, all three studies
had methodological shortcomings. Only one small study,
with 127 patients, used a cohort of patients that is con-
sidered the best source of prognostic information [8, 10].
All three studies used complete cases, excluding cases
with missing data, analysis without justifying the as-
sumptions underlying this approach; given the potential
non-random distribution of missing data, the results
might be biased [11]. In addition, none of them validated
internally their model and they did not present calibra-
tion or discrimination measures. Hence, they might be
at risk of misspecification [12]. In addition, none of them
used shrinkage to avoid overfitted models [13]. Finally,
none of the studies evaluated the clinical benefit of the
model, an essential step, which quantifies whether and
to what extent a prognostic model is potentially useful
in decision-making and clinical practice. Similar limita-
tions exist in other published prognostic models, which
commonly have serious deficiencies in the statistical
methods, are based on small datasets and have inappro-
priate handling of missing data and lack validation [14].
In this research work, we aim to fill the gap of prog-
nostic models on relapses for RRMS patients. We
present the development, the internal validation, and the
evaluation of the clinical benefit of a prognostic model
for relapses for individuals with RRMS using real-world
data from the Swiss Multiple Sclerosis Cohort (SMSC)
[15]. The cohort is comprised of patients diagnosed with
RRMS who are followed bi-annually or annually in
major MS centres with full standardized neurological ex-
aminations, MRIs and laboratory investigations [15].
Our prognostic model is designed for a patient who,
within the Swiss health care system and standard MS
treatment protocols, would like to estimate their prob-
ability of having at least one relapse within the next 2
years.
Data and methods
In “Data description”, we describe the data available for
the model development. We followed seven steps (de-
scribed in detail in “Steps in building the prognostic
model”) to build and evaluate the prognostic model: (1)
selection of prognostic factors via a review of the litera-
ture, (2) development of a generalized linear mixed-
effects model in a Bayesian framework, (3) examination
of sample size efficiency, (4) shrinkage of the coeffi-
cients, (5) dealing with missing data using multiple im-
putations, (6) internal validation of the model. Finally,
we evaluated the potential clinical benefit of the devel-
oped prognostic model. For the development and the
validation of our prognostic model we followed the TRI-
POD statement [16]; the TRIPOD checklist is presented
in Appendix Table 3.
Data description
We analysed observational data on patients diagnosed
with relapsing-remitting multiple sclerosis (RRMS) pro-
vided by the Swiss Multiple Sclerosis Cohort (SMSC))
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study [15], which has been recruiting patients since June
2012. SMSC is a prospective multicentre cohort study
performed across seven Swiss centres. Every patient in-
cluded in the cohort is followed up every 6 or 12
months, and the occurrence of relapses, disability pro-
gression, DMTs initiation or interruption, adverse
events, and concomitant medications are recorded at
each visit. Brain MRI and serum samples are also col-
lected at each visit. The strength of SMSC is the high
quality of data collected including MRI scans and body
fluid samples in a large group of patients. In addition,
several internal controls and validation procedures are
performed to ensure the quality of the data.
We included patients with at least 2 years of follow-
up. The drop-out rate in the entire SMSC cohort was
15.8%. Drop-out was primarily associated with change of
address and health care provided by a physician not as-
sociated with SMSC. Therefore, we assume that patients
dropping out of the cohort before completing 2 years
were not more likely to have relapsed than those
remaining in the cohort, and hence the risk of attrition
bias is low. The dataset includes 935 patients, and each
patient has one, two, or three 2-year follow-up cycles. At
the end of each 2-year cycle, we measured relapse occur-
rence as a dichotomous outcome. At the beginning of
each cycle, several patient characteristics are measured
and we considered them as baseline characteristics for
this specific cycle. In total, we included 1752 cycles from
the 935 study participants. Patients could be prescribed
several potential DMTs during their follow-up period,
i.e. a patient during a 2-year follow-up cycle could either
take no DMT or one of the available DMTs. We used
the treatment status only at baseline of each 2-year cycle
to define the dichotomous prognostic factor “currently
on treatment” or not.
We transformed some of the continuous variables to
better approximate normal distributions and merged
categories with very low frequencies in categorical vari-
ables. Table 1 presents summary statistics of some im-
portant baseline characteristics using all cycles (n =
1752), while in Appendix Table 4, we present the out-
come of interest (frequency of relapse within 2 years), as
well as several baseline characteristics separately for pa-
tients that were included in 1 cycle, patients that were
included in 2 cycles, and patients that were included in
3 cycles.
Notation
Let Yij denote the dichotomous outcome for individual
i where i=1, 2, …, n at the jth 2-year follow-up cycle out
of ci cycles. PFijk is the k
th prognostic factor k=1,…,np.
An individual develops the outcome (Yij = 1) or not (Yij =
0) according to its probability pij.
Steps in building the prognostic model
Step 1—Selection of prognostic factors
Developing a model using a set of predictors informed
by prior knowledge (either in the form of expert opinion
Table 1 Summary statistics of some important baseline
characteristics using all 1752 2-year cycles coming from 935
unique patients in SMSC
Characteristics Number of observations (n = 1752)
Relapse within 2 years
Yes
n (%) 302 (17.2)
No
n (%) 1450 (82.8)
Gender
Females
n (%) 1209 (69)
Males
n (%) 543 (31)
Currently on treatment
Yes
n (%) 1639 (93.6)
No
n (%) 113 (6.4)
NA
n (%) 34 (2.0)
Age








mean ± sd 2.4 ± 1.4
min 0.0
max 7.0
Number of gadolinium-enhanced lesions
= 0
n (%) 956 (55.0)
= 1
n (%) 26 (1.0)
≥ 2
n (%) 25 (1.0)
NA
n (%) 745 (43.0)
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or previously identified variables in other prognostic
studies) has conceptual and computational advantages
[17, 18, 19]. Hence, in addition to the information ob-
tained from the three prognostic models included in the
recent systematic review discussed in introduction 7, 9,
10, we aimed to increase our relevant information, via
searching for prediction models or research works aim-
ing to identify subgroups of patients in RMMS. We
searched in PubMed (https://pubmed.ncbi.nlm.nih.gov),
using the string ((((predict*[Title/Abstract] OR prognos*[-
Title/Abstract])) AND Relapsing Remitting Multiple
Sclerosis[Title/Abstract]) AND relaps*[Title/Abstract])
AND model[Title/Abstract]. We then decided to build a
model with all prognostic factors included in at least
two of the previously published models.
Step 2—Logistic mixed-effects model
We developed a logistic mixed-effects model in a Bayes-
ian framework:
Model 1








  PFi;k; j
We used fixed-effect intercept (β0), fixed-effect slopes
(βk), individual-level random effects intercept (uoi), and
individual-level random effects slopes (uki) to account
for information about the same patient from different
cycles.
We define u¼ uo
uk
 
to be the (np + 1) × n matrix of
all random parameters and we assume it is normally dis-
tributed u~N(0,Du) with mean zero and a (np +
1) × (np + 1) variance-covariance matrix
Du ¼













This structure assumes that the variances of the im-
pact of the variables on multiple observations for the
same individual are equal (σ2) and that the covariances
between the effects of the variables are equal too
(ρ × σ2).
Step 3—Examination of sample size efficiency
We examined if the available sample size was enough for
the development of a prognostic model [16]. We calcu-
lated the events per variable (EPV) accounting for both
fixed-effects and random-effects and for categorical
variables [20]. We also used the method by Riley et al. to
calculate the efficient sample size for the development of
a logistic regression model, using the R package
pmsampsize [21]. We set Nagelkerke’s R2 = 0.15 (Cox-
Snell’s adjusted R2 = 0.09) and the desired shrinkage
equal to 0.9 as recommended [21].
Step 4—Shrinkage of the coefficients
The estimated effects of the covariates need some form
of penalization to avoid extreme predictions [13, 22]. In
a Bayesian setting, recommended shrinkage methods use
a prior on the regression coefficients [23]. For logistic re-
gression, a Laplace prior distribution for the regression
coefficients is recommended [24] (i.e. double exponen-
tial, also called Bayesian LASSO)








where λ is the shrinkage parameter. A Laplace prior al-
lows small coefficients to shrink towards 0 faster, while
it applies smaller shrinkage to large coefficients [25].
Step 5—Multiple imputations for missing data
In the case of missing values in the covariates, we as-
sumed that these are missing at random (MAR), mean-
ing that, given the observed data, the occurrence of
missing values is independent of the actual missing
values. Appropriate multiple imputation models should
provide valid and efficient estimates if data are MAR. As
our substantive model is hierarchical, we used Multilevel
Joint Modelling Multiple imputations using the mitml R
package [26].
First, we checked for variables not included in the sub-
stantive model that could predict the missing values (i.e.
auxiliary variables). Then, we built the imputation
model, using both fixed-effect and individual-level ran-
dom effects intercept and slopes as in our substantive
(Model 1), where the dependent variables are the vari-
ables that include missing values for imputation, and the
independent variables are all complete variables included
in the substantive model and the identified auxiliary
variables.
We generated 10 imputed datasets, using the jomoIm-
pute R function, and we applied the Bayesian model
(Model 1) to each of the imputed datasets. We checked
convergence of the imputations using the plot R func-
tion in the mitml R package. Finally, we obtained the
pooled estimates for the regression coefficients, bβ0 andbβk , using Rubin’s rules [27] (testEstimates R function)
with two matrices containing the mean and the vari-
ances estimates, respectively, from each imputed dataset
as arguments.
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Step 6—Internal validation
First, we assessed the calibration ability of the developed
model, via a calibration plot with loess smoother, for the
agreement between the estimated probabilities of the
outcome and the observed outcome’s proportion (val.-
prob.ci.2 R function). We used bootstrap internal valid-
ation to correct for optimism in the calibration slope
and in discrimination, measured via the AUC [13]. For
each one of the 10 imputed datasets, we created 500
bootstrap samples and in each one of them: (1) we con-
structed a generalized linear model with the pre-
specified predictors, using the glm R function, denoted
as Model*, (2) we calculated the bootstrap performance
as the apparent performance of Model* on the sample
for each one of the bootstrap samples, (3) we applied the
Model* to the corresponding imputed dataset to deter-
mine the test performance, (4) we calculated the opti-
mism as the difference between bootstrap performance
and test performance. Then, we calculated the average
optimism between the 500 bootstrap samples and used
Rubin’s rules to summarize the optimism for the AUC
and the calibration slope between the 10 imputed data-
sets. We calculated the optimism-corrected AUC and
calibration slope of our prognostic model, by subtracting
the optimism estimate from the apparent performance.
Ideally, we should construct the Bayesian logistic
mixed-effects model exactly as we developed the original
model. However, this would need 15000 h to run, as the
Bayesian model needs to run for 500 bootstrap samples
in each one of the 10 imputed datasets (i.e. 5000 times)
and the Bayesian model itself needs 3 h, and hence, the
bootstrap internal validation we performed results to a
rough optimism estimation ignoring the dependence be-
tween the same individual.
We used self-programming R routines to validate the
model via bootstrapping.
Clinical benefit of the developed model
Decision curve analysis is a widely used method to
evaluate the clinical consequences of a prognostic
model. This method aims to overcome some weaknesses
of the traditional measures (i.e. discrimination and cali-
bration) that are not informative about the clinical value
of the prognostic model [28]. Briefly, decision curve ana-
lysis calculates a clinical “net benefit” for a prognostic
model and compares it in with the default strategies of
treat all or treat none of the patients. Net benefit (NB) is
calculated across a range of threshold probabilities, de-
fined as the minimum probability of the outcome for
which a decision will be made.
More detailed, information about their risk of relaps-
ing within the next 2 years might be important to help
patients to re-consider whether their current treatment
and approach should continue to follow the established
standards of care in Switzerland. If the probability of re-
lapsing is considered too high, maybe RRMS patients
would be interested in taking a more radical stance to-
wards the management of their condition: discuss with
their treating doctors about more active disease-
modifying drugs (which might also have a high risk of
serious adverse events), explore the possibility of stem
cell transplantation etc. Let us call this the “more active
approach”. If the probability of relapsing is higher than a
threshold α% then a patient will take a “more active ap-
proach” to the management of their condition; other-
wise, they will continue “as per standard care”.
We examined the net benefit of our final model, via
the estimated probabilities provided, by using decision
curve analysis and plotting the NB of the developed
prognostic model, using the dca R function, in a range
of threshold probabilities α% that is equal to
NBdecision based on the model= ðTrue positive%Þ−ð
False positive%Þ  a%1−a% .
We compare the results with those from two default
strategies: recommend “as per standard care for all” and
continue “more active approach for all”. The NB of “as
per standard care for all” is equal to zero in the whole
range of the threshold probabilities, as there are no false
positives and false negatives. “More active approach for
all” does not imply that the threshold probability a% has
been set to 0 and is calculated for the whole range of
threshold probabilities using the formula:
NBmore active approach for all ¼ ðprevalenceÞ−ð1−prevalenceÞ
 a%1−a%
These two strategies mean the more active treatment
options will be discussed and considered by all patients
(“more active approach for all”) or with none (“as per
standard care for all”). A decision based on a prognostic
model is only clinically useful at threshold a% if it has a
higher NB than both “more active approach for all” and
(“as per standard care for all”). If a prognostic model has
a lower NB than any default strategy, the model is con-
sidered clinically harmful, as one of the default strategies
leads to better decisions [28, 29, 30, 31, 32].




For the model development, we used 1752 observations
coming from 2-year repeated cycles of 935 patients who
experienced 302 relapses.
First, we took into account the three prognostic
models included in the recent systematic review [7, 9,
10] that predict relapse (not the treatment response to
relapses) in patients with RRMS. Our search in PubMed
identified 87 research articles. After reading the
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abstracts, we ended up with seven models that predicted
either relapses or treatment response to relapses. Three
of them were already included in the recent systematic
review, as they predicted relapses. Hence, we identified
three additional models that predict the treatment re-
sponse to relapses [33, 34, 35], and one research work
aiming to identify subgroups of RRMS patients who are
more responsive to treatments [36].
Figure 1 shows which prognostic factors were selected
and which pre-existing prognostic models were included
[7, 9, 33, 34, 35, 36]. We included none of the prognostic
factors included in Liguori et. al.’s [10] model, as none
of the prognostic factors they used (i.e. MRI predictors)
were included in any other of the available models. We
briefly summarize these models in Section 1 of the Ap-
pendix file, and some important characteristics of these
models are shown in Appendix Table 5.
The prognostic factors included in our model are pre-
sented in Table 2 with their pooled estimated bβk , ORs
and their corresponding 95% credible intervals (CrIs).
We have also developed a web application where the
personalized probabilities to relapse within 2 years are
calculated automatically. This is available for use in a R
Shiny app https://cinema.ispm.unibe.ch/shinies/rrms/. In
this example the variance σ2 is estimated 0.0001 and the
covariance ρ × σ2 are equal to 0.00005. Hence, the ran-
dom intercept and all random slopes were estimated
close to 0. For convenience and speed of estimation, pre-
dictions were made using only the fixed effects esti-
mates. In the Supplementary file, Appendix Table 6, we
present the estimated coefficients in each of the ten im-
puted datasets.
The full model’s degrees of freedom were 22 (for 10
predictors with random intercept and slope) and the
events per variable (EPV) was 13.7. The efficient sample
size was calculated as 2084 (to avoid optimism in the re-
gression coefficients), 687 (for agreement between ap-
parent and adjusted model performance), and 220 (for a
precise estimation of risk in the whole population) [21].
Our available sample size suggests that there might be
optimism in our regression coefficients. However, this
should have been addressed via the shrinkage we
performed.
In Fig. 2, we show the distributions of the calculated
probability of relapsing for individuals by relapse status.
The overlap in the distributions of the probabilities is
large, as also shown by the optimism-corrected AUC
(Table 2). The overall mean probability of relapsing is
19.1%. For patients who relapsed the corresponding
mean is 23.4% whereas for patients who did not relapse
is 18.0%. Figure 3 shows the calibration plot, with some
apparent performance measures and their 95% confi-
dence intervals (CIs), of the developed prognostic
models and represents the agreement between the
Fig. 1 Venn diagram of the prognostic factors included at least two times in pre-existing models and included in our prognostic model. The
names with an asterisk refer to the first author of each prognostic model or prognostic factor research [ 7, 9, 10, 33, 34, 35, 36]. . EDSS, Expanded
Disability Status Scale; Gd, gadolinium
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estimated probabilities and the observed proportion to
relapse within 2 years.
In Fig. 4, the exploration of the net benefit of our prognos-
tic model is presented [ 29, 30, 31, 32]. In the figure, the ver-
tical axis corresponds to the NB and the horizontal axis
corresponds to the preferences presented as threshold prob-
abilities. The NB is a weight between the benefit of identify-
ing, and consequently correctly treating, individuals that
relapsed and the harm (e.g. side effects) of wrongly prescrib-
ing patients the “more active approach” due to false positives
results. Threshold probabilities refer to how decision makers
value the risk of relapsing related to a harmful condition for
a given patient, a decision that is often influenced by a dis-
cussion between the decision maker and the patient. It is eas-
ily seen that the dashed line, corresponding to decisions
based on the developed prognostic model, has the highest
NB compared to default strategies, between the range 15
and 30% of the threshold probabilities. Nearly half of the pa-
tients (46.5%) in our dataset have calculated probabilities be-
tween these ranges, in at least one follow-up cycle. Hence,
for patients that consider the relapse occurrence to be 3.3 to
6.6 times worse ( 1a%) than the risks, costs, and inconvenience
in “more active approach”, the prognostic model can lead to
better decisions than the default strategies.
Table 2 Pooled estimates of the regression coefficients cβk; ORs and the 95% CrIs for each one of the parameters in the model
(centralized to the mean), using Rubin’s rules. The estimated σ (standard deviation of the impact of the variables on multiple
observations for the same individuals) is 0.01. The estimated correlation ρ between the effects of the variables is 0.49. The pooled
optimism-corrected AUC is 0.65 and the pooled optimism-corrected calibration slope is 0.91. Disease duration was transformed to
log(disease duration+10), and months since last relapse was transformed to log(months since last relapse+10)
Parameters bβk OR 95% CrI
Age -0.035 0.97 (0.95, 0.98)
Disease duration 0.337 1.40 (0.90, 2.18)
EDSS 0.122 1.13 (1.02, 1.25)
Number of gadolinium-enhanced lesions (> 0 vs 0) − 0.034 0.97 (0.69, 1.36)
Number of previous relapses (1 vs 0) − 0.070 0.93 (0.69, 1.26)
Number of previous relapses (2 or more vs 0) 0.133 1.14 (0.81, 1.61)
Months since last relapse − 0.478 0.62 (0.49, 0.78)
Treatment naïve (yes vs no) 0.086 1.09 (0.80, 1.49)
Gender (female vs male) 0.254 1.29 (0.97, 1.72)
On treatment (yes vs no) − 0.221 0.80 (0.50, 1.27)
Fig. 2 The distribution of probability of relapsing within the next 2 years by relapse status at the end of 2-year follow-up cycles. The dashed lines
indicate the mean of estimated probability/risk for cycles that ended up with relapse (purple) and for those without relapse (yellow)
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Discussion
We developed a prognostic model that predicts re-
lapse within 2 years for individuals diagnosed with
RRMS, using observational data from the SMSC [15],
a prospective multicenter cohort study, to inform
clinical decisions. Prognostication is essential for the
disease management of RRMS patients, and until
now, no widely accepted prognostic model for MS is
used in clinical practice. A recent systematic review
on prognostic models for RRMS [8], describes that
most of the prognostic models, regardless of the out-
come of interest, are lacking statistical quality in the
development steps, introducing potential bias, did
not perform internal validation, did not report im-
portant performance measures like calibration and
discrimination, and did not present the clinical im-
pact of the models. More specifically, only three
studies examined the relapses as an outcome of
interest and none of them satisfied the criteria above.
Our model aimed to fill the existing gap, by satisfy-
ing all the above criteria, to enhance the available in-
formation for predicting relapses and to inform
decision-making.
Given that a manageable number of characteristics is
needed to establish the risk score, doctors and patients
can enter these using our online tool (https://cinema.
ispm.unibe.ch/shinies/rrms/), estimate the probability of
relapsing within the next 2 years, and take treatment de-
cisions based on patient’s risk score. This tool shows the
potential of the proposed approach, however, may not
yet be ready for use in clinical practice, as decision-
making tools need external validation with an independ-
ent cohort of patients.
We included eight prognostic factors (all measured at
baseline where also the risk was estimated): age, disease
duration, EDSS, number of gadolinium-enhanced le-
sions, number of previous relapses 2 years prior, months
since last relapse, treatment naïve, gender, and “cur-
rently on treatment”. The EPV of our model is 13.7, the
sample size is efficient enough, and more than the sam-
ple size of all three pre-existing prognostic models. The
optimism corrected AUC of our model is 0.65, indicat-
ing a relatively small discrimination ability of the model.
However, in the literature, only Stühler et. al. reported
the AUC of their model that was also equal to 0.65. In
our previous work [37], the optimism corrected AUC
Fig. 3 Calibration plot (N = 1752) of the developed prognostic model with loess smoother. The distribution of the estimated probabilities is
shown at the bottom of the graph, by status relapse within 2 years (i.e. events and non-events). The horizontal axis represents the expected
probability of relapsing within the next 2 years and the vertical axis represents the observed proportion of relapse. The apparent performance
measures (c-statistic and c-slope) with their correspondent 95% CI are also shown in the graph
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using the LASSO model, with many candidate predic-
tors, was 0.60, whereas this of the pre-specified model
was 0.62. This could indicate that, in general, relapses
are associated with unknown factors. The prognostic
model we developed seems to be potentially useful, pre-
ferred over “Treat all” or “Treat none” approaches for
threshold ranges between 15 and 30%.
The applicability of our model is limited by several
factors. First, the risk of relapsing is not the only out-
come that patients will consider when making deci-
sions; long-term disability status would also determine
their choice [4], and there is an ongoing debate of
whether the relapse rate is associated with the long-
term disability [ 5, 6, 7, 38]. That could be a further
line of future research, and prognostic models with
good statistical quality for long-term disability still
need to be developed. In addition, the sample size of
the SMSC is relatively small compared to other ob-
servational studies; this study though is of high qual-
ity. Furthermore, the bootstrap internal validation we
performed ignores the dependence between the same
individuals. In each one of the 10 imputed datasets
and the 500 bootstrap samples, we constructed a fre-
quentist logistic linear model. Ideally, we should con-
struct the Bayesian logistic mixed-effects model
exactly as we developed the original model. In
addition, for model parsimony reasons, our model as-
sumes that the variances of the impact of the vari-
ables on multiple observations for the same individual
are equal and that the covariances between the effects
of the variables are equal too. This assumption might
be relaxed by, e.g. assuming covariate-specific correla-
tions. Finally, our model was not validated externally,
something essential for decision-making tools. In the
near future, independent researchers, as recommended
by Colins et. al. [39], should validate externally our
model before it is ready for clinical use.
Conclusions
The prognostic model we developed offers several
advantages in comparison to previously published
prognostic models in RRMS. We performed multiple
imputations for the missing data to avoid potential
bias induced [11], we used shrinkage of the
Fig. 4 Decision curve analysis showing the net benefit of the prognostic model per cycle. The horizontal axis is the threshold estimated
probability of relapsing within 2 years, a%, and the vertical axis is the net benefit. The plot compares the clinical benefit of three approaches: “as
per standard care for all” approach, “more active care for all” approach, and “decision based on the prognostic model” approach (see definitions
in “Clinical benefit of the developed model”). For a given threshold probability, the approach with the highest net benefit is considered the most
clinically useful model. The “decision based on the prognostic model” approach provides the highest net benefit for threshold probabilities
ranging from 15 to 30%
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coefficients to avoid overfitting [13], and we validated
internally our model presenting calibration and dis-
crimination measures, an essential step in prognosis
research [13]. Importantly, we assessed the net bene-
fit of our prognostic model, which helps to quantify
the potential clinical impact of the model. Our web
application, when externally validated, could be used
by patients and doctors to calculate the individual-
ized risk of relapsing within the next 2 years and to
inform their decision-making.
Appendix
Section 1. Summary of pre-existing models on RRMS used
in our model
1. Held et al. [9] aimed to determine the
contribution of different possible prognostic
factors available at baseline to the relapse rate in
MS. The authors used 821 patients from the
placebo arms of the Sylvia Lawry Centre for
Multiple Sclerosis Research (SLCMSR) database.
The relapse number prior to entry into clinical
trials together with disease duration were
identified as the best predictors for the relapse
rate. The authors validated their model, by
splitting the datasets into two samples: the
training setting and the validation setting.
2. Kalincik et al. [35] presented an individualized
prediction model using demographic and clinical
predictors in patients with MS. Treatment response
was analysed separately for disability progression,
disability regression, relapse frequency, conversion
to secondary progressive disease, change in the
cumulative disease burden, and the probability of
treatment discontinuation. They used a large cohort
study, MSBase, with seven disease-modifying ther-
apies. They validated externally the prediction
model in a geographically distinct cohort, the Swed-
ish Multiple Sclerosis Registry. Pre-treatment re-
lapse activity and age were associated with the
relapse incidence.
3. Liquori et al. [10] aimed to investigate the
prognostic value of 1-year subtraction MRI
(sMRI) on change in T2 lesion volume, relapse
rate, and change in brain parenchyma fraction.
They used 127 patients from a cohort followed
in a single centre, the Partners MS Center. They
used only MRI and sMRI measures as prognostic
factors.
4. Pellegrini et al. [34] developed a prediction model to
predict treatment response in patients with
relapsing-remitting multiple sclerosis, using an indi-
vidual treatment response score, regressing on a set
of baseline predictors. They used two randomized
clinical trials: CONFIRM and DEFINE studies. The
outcome of interest was the annualized relapse rate.
The prognostic factors they used are age, short
form-36 mental component summary, short form-
36 physical component summary, visual function
test 2.5%, prior MS treatment (yes or no), EDSS,
timed 25-foot walk, paced auditory serial addition
test (known as PASAT), months since last relapse,
number of prior relapses, 9-hole peg test, ethnicity,
and sex.
5. Signori et al. [36] aimed to examine whether
there are subgroups of RRMS patients who are
more responsive to treatments. 9-Hole Peg Test
he collect all published randomized clinical trials
in RRMS reporting a subgroup analysis of treat-
ment effect. Two main outcomes were studied:
the annualized relapse rate and the disability pro-
gression. The authors meta-analysed the results
of the identified studies to compare the relative
treatment effects between subgroups. Age, gado-
linium activity, and EDSS were identified as the
statistically important subgroups regarding the re-
sponse to treatments for annualized relapse rate.
6. Sormani et al. [7] developed and validated a
prognostic model to identify RRMS patients with a
high risk of experiencing relapses in the short term.
They used 539 patients from the placebo arm of a
double-blind, placebo-controlled trial (CORAL
study) of oral glatiramer acetate in RRMS. The val-
idation sample consisted of 117 patients from the
placebo arm of a double-blind, placebo-controlled
trial of subcutaneous glatiramer acetate in RRMS
(European/Canadian Glatiramer Acetate study).
The variables included in the final model as inde-
pendent predictors of relapse occurrence were the
number of gadolinium-enhanced lesions and the
number of previous relapses.
7. Stühler et al. [33] presented a framework for
personalized prediction model of treatment
response based on real-world data from the
NeuroTransData network for patients diagnosed
with RRMS. They examined two outcomes of
interest: the number of relapses and the disability
progression. They used three different approaches
(10-fold cross-validation, leave-one-site-out cross-
validation, and excluding a test set) to validate
their model. The predictors included for the
number of relapses are age, gender, EDSS,
current treatment, previous treatment, disease
duration, months since last relapse, number of
prior relapses, number of prior therapies, prior
second-line therapy (yes or no), duration of the
current treatment, duration of the previous treat-
ment, and clinical site.
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Table 3 TRIPOD checklist was followed for the development and the validation of the prognostic model
Section/topic Item Checklist item Page
Title and abstract
Title 1 Identify the study as developing and/or validating a multivariable prediction model, the target
population, and the outcome to be predicted.
1
Abstract 2 Provide a summary of objectives, study design, setting, participants, sample size, predictors, outcome,





3a Explain the medical context (including whether diagnostic or prognostic) and rationale for
developing or validating the multivariable prediction model, including references to existing models.
3–4




Source of data 4a Describe the study design or source of data (e.g. randomized trial, cohort, or registry data), separately
for the development and validation data sets, if applicable.
5
4b Specify the key study dates, including start of accrual, end of accrual, and, if applicable, end of follow-
up.
5
Participants 5a Specify key elements of the study setting (e.g. primary care, secondary care, general population)
including number and location of centres.
5–6
5b Describe eligibility criteria for participants. 5–6
5c Give details of treatments received, if relevant. 5–6
Outcome 6a Clearly define the outcome that is predicted by the prediction model, including how and when
assessed.
4,6
6b Report any actions to blind assessment of the outcome to be predicted. Not relevant
Predictors 7a Clearly define all predictors used in developing or validating the multivariable prediction model,
including how and when they were measured.
7, 13, 16, Fig. 1
7b Report any actions to blind assessment of predictors for the outcome and other predictors. Not relevant
Sample size 8 Explain how the study size was arrived at. 8, 14
Missing data 9 Describe how missing data were handled (e.g. complete-case analysis, single imputation, multiple im-




10a Describe how predictors were handled in the analyses. 7–10
10b Specify type of model, all model-building procedures (including any predictor selection), and method
for internal validation.
7–10
10d Specify all measures used to assess model performance and, if relevant, to compare multiple models. 10–12
Risk groups 11 Provide details on how risk groups were created, if done. Not relevant
Results
Participants 13a Describe the flow of participants through the study, including the number of participants with and
without the outcome and, if applicable, a summary of the follow-up time. A diagram may be helpful.
Table 1 and
Appendix Table 4
13b Describe the characteristics of the participants (basic demographics, clinical features, available





14a Specify the number of participants and outcome events in each analysis. Table 1 and
Appendix Table 4
14b If done, report the unadjusted association between each candidate predictor and outcome. Not relevant
Model
specification
15a Present the full prediction model to allow predictions for individuals (i.e., all regression coefficients,
and model intercept or baseline survival at a given time point).
Table 2
15b Explain how to use the prediction model. 13, 15
Model
performance
16 Report performance measures (with CIs) for the prediction model. 13, Table 2
Discussion
Limitations 18 Discuss any limitations of the study (such as nonrepresentative sample, few events per predictor,
missing data).
16–17
Interpretation 19b Give an overall interpretation of the results, considering objectives, limitations, and results from similar 15–17
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Table 3 TRIPOD checklist was followed for the development and the validation of the prognostic model (Continued)
Section/topic Item Checklist item Page
studies, and other relevant evidence.




21 Provide information about the availability of supplementary resources, such as study protocol, Web
calculator, and data sets.
12, 13, 15
Funding 22 Give the source of funding and the role of the funders for the present study. 29
Table 4 Frequency of relapse within 2 years and frequency of treatment per cycle for patients that were included in one cycle only,
patients that were included in two cycles and patients that were included in three cycles. Gender, age, and EDSS at the beginning
of the 1st cycle separately for patients with one cycle only, with two cycles, and with three cycles. Individuals with one cycle are




Cycle Relapses Treated Female Age EDSS
Mean (sd) Mean (sd)
One 324 1 62 (19%) 281 (87%) 203 (63%) 39.6 (11.6) 2.3 (1.5)
Two 405 1 82 (20%) 360 (89%) 556 (69%) 40.7 (11.0) 2.3 (1.3)
2 50 (12%) 398 (98%)
Three 206 1 47 (23%) 184 (89%) 450 (73%) 42.6 (10.8) 2.5 (1.4)
2 44 (22%) 196 (95%)
3 17 (8%) 199 (97%)
Chalkou et al. Diagnostic and Prognostic Research            (2021) 5:17 Page 12 of 16
Table 5 Characteristics of the studies used to inform the developed prognostic model
Study Design Sample
size (EPV)
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